Oncolytics Biotech Inc. has announced that it expects to receive the final grant payment from the Pancreatic Cancer Action Network (PanCAN) as part of its GOBLET clinical study. This update is significant as it marks the conclusion of enrollment activities for the study, which is crucial in the development of new therapies for pancreatic cancer.
Oncolytics Biotech, based in San Diego, California, operates in the pharmaceutical preparations sector. The company is known for developing pelareorep, a novel immunotherapy that is currently being evaluated in various clinical studies, including the GOBLET study. The company trades under the ticker ONCY on the Nasdaq exchange.
According to the recent filing, Oncolytics stated, "On October 14, 2026, Oncolytics Biotech Inc. issued a press release announcing it is expecting to receive the final grant payment from the Pancreatic Cancer Action Network later this quarter as part of wind-down enrollment activities in the GOBLET clinical study." The company also mentioned that it anticipates reporting additional clinical data from GOBLET Cohort 4 and 5 in the coming months.
This development may impact various stakeholders, including patients participating in the study, healthcare providers, and investors. The expected clinical data could provide insights into the efficacy of pelareorep in treating pancreatic cancer, which may influence future treatment protocols and market dynamics.
As for the next steps, Oncolytics Biotech has not specified what will happen following this announcement. However, the company is expected to continue monitoring patients and preparing for the upcoming clinical data readouts from the remaining cohorts.